The cytokines interleukin-l and interleukin-2 participate in the inflammatory response, and may contribute to hypergammaglobulinaemia G and the development of 
Interleukin (IL)-la and IL-2 are proinflammatory cytokines produced in response to infectious and immunological stimuli. IL-la is mainly derived from mononuclear phagocytes.
It is chemotactic for granulocytes and induces their degranulation.6 7 IL-la is one of the earliest cytokines produced in response to antigen and may initiate the release of a cascade of other cytokines including IL-2, IL-6, IL-8, and TNF-a.8 9 Cytokine assays were performed on coded specimens by a scientist (MJH) who was unaware of patients' identity, treatment received, and the order in which samples were collected. Immune reactive concentrations of IL-loa were assayed in serum using a two site enzyme linked immunosorbent assay (ELISA). Specimens were analysed in duplicate and unknown values read from standard curves constructed using recombinant IL-la. The lower limit of detection of IL-la was 10 pg/ml.
Immunoreactive concentrations of sIL-2R were measured using two antibodies directed against different epitopes of the TAC portion of the IL-2 receptor in a modification of an ELISA method described elsewhere.'0 The assay sensitivity was 200 IU/ml. Interassay and intra-assay coefficients of variation for both ELISAs were less than 10%. -0-4) ; p<004, and in FVC was +4-7 v -2-0, difference [6] [7] (-17 to 1-0); p=0-08 (table 2) .
STATISTICS
Interleukin In some, a tendency for both parameters to revert to baseline was observed on the alternate day regimen (figure). Increases in unmeasured mediators implicated in cystic fibrosis lung injury (neutrophil elastase, leukotriene B4, other cytokines or adhesion molecules) at the 12 weeks interval cannot be excluded. Although a causal relationship cannot be confirmed, our results suggest that IL-lot and IL-2 are involved in the orchestration of the inflammatory response and the enhanced synthesis of IgG which accompany airflow obstruction in patients with cystic fibrosis. Serum was used to detect immunoreactive concentrations of IL-lot and sIL-2R and therefore we cannot exclude the possibility of cytokine release during the clotting process ex vivo. However, we have previously demonstrated that children with cystic fibrosis have significantly higher serum cytokine concentrations than normal controls24 suggesting that the clotting mechanism per se does not underlie our findings. It is also important to distinguish immunoreactivity from biological activity. Naturally occurring inhibitors of IL-la have been described and the soluble IL-2 receptor may itself compete with membrane boundIL-2 receptors for IL-2. 27 28 In the presence of chronic infection and inflammation, these factors may limit immunologically mediated lung damage by moderating these exaggerated protective responses. Therefore, in the absence of a confirmatory bioassay, we can only speculate as to the biological activity of the IL-la and sIL-2R that we have detected. The finding that improvements in pulmonary function are accompanied by falls in cytokine concentration suggest that the immunoreactivity detected represents biologically important cytokine activity.
The putative mechanism of action of corticosteroids is the induction of lipocortin, a polypeptide that antagonises phospholipase A2. This was believed to limit the release of arachidonic acid from membrane phospholipids and reduce the substrate for both cyclo-oxygenase and 5-lipoxygenase pathways. Short courses of systemic steroids can change pulmonary function and reduce systemic inflammatory cytokine immunoreactivity in clinically stable cystic fibrosis patients. Long term administration of prednisone (2 mg/kg on alternate days) is associated with an unacceptably high incidence of side effects. 35 Data regarding safety and efficacy of a lower dose (1 mg/kg on alternate daysX4 years, US National Collaborative Study) have not been published, and therefore the long term administration of corticosteroids at this dose cannot be recommended. However, our results raise important questions regarding their anti-inflammatory effect in patients with cystic fibrosis, which require further investigation. Firstly, they may represent a useful adjunct to the treatment of infective exacerbations during periods when inflammatory activity can be expected to be greatest. Secondly, more potent and topically active steroid compounds may have beneficial effects on lung function, which permit their long term use, without causing systemic toxicity. Finally, the earlier administration of topical steroids to younger children without overt lung disease who have silent inflammatory activity36 may delay the inevitable decline that occurs in pulmonary function.
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